Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00600353 · ClinicalTrials.gov registry record · Phase 2
Multi-day Doses in Prevention of Nausea and Emesis
A Phase 2 study, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00600353 is a Phase 2 study that has completed, run by University of Kansas Medical Center. The registered enrollment target is 20 participants.
The verdict
NCT00600353, a Phase 2 study, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
To assess emetic responses to multi-day doses of Palonosetron and Aprepitant and low dose dexamethasone +/- Prochlorperazine among patients with multiple myeloma and lymphoma undergoing autologous HSCT utilizing the Multinational Association for Supportive Care in Cancer (MASCC) Antiemesis Tool (MAT).
Interventions
- DRUG Dexamethasone
- DRUG Palonosetron
- DRUG Aprepitant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-10 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00600353
The ClinicalTrials.gov registry entry for NCT00600353 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT00600353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00600353 about?
NCT00600353 is a clinical study titled "Multi-day Doses in Prevention of Nausea and Emesis". To assess emetic responses to multi-day doses of Palonosetron and Aprepitant and low dose dexamethasone +/- Prochlorperazine among patients with multiple myeloma and lymphoma undergoing autologous HSCT utilizing the Multinational Association for Supportive Care in Cancer (MASCC) Antiemesis Tool (MAT...
What is the current status of trial NCT00600353?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2007-10. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00600353?
The interventions under investigation include: Dexamethasone (DRUG), Palonosetron (DRUG), Aprepitant (DRUG).
Who is sponsoring clinical trial NCT00600353?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.